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ed may be due to a variety of mecha-
nisms, not just inhibition of angiogenesis.
Given the fact that antiangiogenic
drugs are mainly used in combination
with chemotherapy, an obvious question
is whether relapses observed in patients
who are treated with a targeted drug
such as bevacizumab with chemothera-
py occur mainly as a consequence of
development of resistance to the target-
ed antiangiogenic drug in a manner simi-
lar to that described by Casanovas et al.,
or alternatively, to the chemotherapy
component of the regimen. If it is the for-
mer, the need for discontinuation of the
antiangiogenic drug therapy is obvious,
along with its possible replacement by
another drug that has a good chance of
showing resurrecting efficacy. If it is the
latter, continued use of the original
antiangiogenic drug and a change in
chemotherapy would be called for.
Considering the therapeutic conse-
quences of making the right (or wrong)
decision, as well as the enormous eco-
nomic implications, given the huge cost
of many new anti-cancer drugs, distin-
guishing between the two will obviously
assume an obvious degree of future
importance. Viewed from this perspec-
tive, the results of Casanovas et al., and
also of Mizukami et al. (2005) firmly
establish the multiplicity of compensato-
ry angiogenic pathways available to can-
cer cells as a likely cause of resistance
to specific targeted antiangiogenic
drugs, and suggest potential strategies
to delay such resistance, thus facilitating
not only their intrinsic antiangiogenic
properties, but their chemosensitizing
effects as well.
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This issue of Cancer Cell carries a report
of experiments with a mouse model of
the most common hereditary condition
facing the pediatric oncologist, neurofi-
bromatosis type 1 (NF1) (Chao et al.,
2005). Shannon and colleagues used
adolescent and young adult mice that
carry a mutation in Nf1, the gene respon-
sible for NF1, to study cancer resulting
from the effects of cytotoxic therapy in
genetically susceptible individuals. Mice
heterozygous for that mutation devel-
oped second malignant neoplasms
(SMNs) with or without the admin-
istration of radiation (RAD) and/or
chemotherapy with an alkylating agent
(cyclophosphamide [CY]) at a signifi-
cantly higher rate than wild-type controls
who were similarly treated (51/81 com-
pared to 17/100).
It was inevitable that I would be excit-
ed about this report, since the interaction
of therapy and genetic predisposition in
the etiology of SMNs has preoccupied
me during the past 30 years of my work
with survivors of childhood cancer.
During the decade of the 1970s, as it
became evident that children with cancer
would be able to survive for many years
after receiving treatment, concerns
began to be expressed regarding the
long-term effects of the RAD and
chemotherapy responsible for cure. With
colleagues at the National Cancer
Institute and three major pediatric oncol-
ogy centers, I embarked on a study of
late effects, especially SMNs, in sur-
vivors of childhood cancers.
Our report published in 1985 on the
spectrum of 308 SMNs in 292 childhood
cancer survivors seen at 13 institutions in
the United States, Canada, and Europe
noted that 68% had developed in a tissue
that had been exposed to RAD, that bone
and soft tissue sarcomas were the most
A mouse model for studying therapy-induced cancers
As more pediatric cancer patients survive for longer periods following treatment with cytotoxic agents, therapy-induced
second malignant neoplasms (SMNs) have become a major concern. In this issue of Cancer Cell, Chao et al. report that
mice carrying a mutation in Nf1, the gene responsible for neurofibromatosis type 1, treated with radiation and/or
cyclophosphamide, developed tumors similar to human SMNs at a significantly higher rate than did wild-type controls
treated similarly.This model provides efficient and rational means for testing procedures and agents that could inform clin-
icians regarding second cancer risks associated with treatment and, perhaps, reducing them.
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frequent, and that 52 of 67 bone tumors
and 43 of 59 soft tissue sarcomas
occurred in tissues exposed to RAD
(Meadows et al., 1985). Since then, there
have been numerous reports attesting to
the role of therapy, notably RAD and
some chemotherapeutic agents, in the eti-
ology of SMNs in both children and adults,
and we have learned much (Meadows,
2001; Rheingold et al., 2005). We know
that RAD is the most common etiological
factor in SMNs, that there is a dose
response for tumors of bone and soft tis-
sues (Tucker et al., 1987a), that young
age and lower doses of RAD increase the
risk of thyroid cancer (Sigurdson et al.,
2005), that breast cancer continues to
increase for years in young women who
have been treated with RAD for Hodgkin’s
disease (Bhatia et al., 2003; Travis et al.,
2003), and that certain alkylating agents
and topoisomerase 2 inhibitors, depend-
ing on dose and schedule, are associated
with secondary leukemias (Bhatia et al.,
1999; Felix, 1999).
There were some children in that
earlier cohort who developed SMNs
because they were obviously predis-
posed: children with the hereditary form
of retinoblastoma and children with NF1.
Although these conditions remain the
most common syndromes among chil-
dren who develop SMNs after childhood
cancer treatment and have been the
most widely studied, other, less common
genetic conditions associated with can-
cer, whose genes have been cloned,
might also serve as models for mecha-
nisms of transformation (Table 1).
In the hereditary form of retinoblas-
toma, marked by a constitutional mutation
in RB1, an increased risk for SMNs
imposed by RAD has been well docu-
mented (Wong et al., 1997). However,
there have not yet been data demonstrat-
ing an unequivocally increased risk fol-
lowing RAD in humans with NF1. The
results of these experiments in this animal
model may provide sufficient evidence to
convince any remaining skeptics.
Since the tumors that NF1 children
develop either spontaneously or follow-
ing therapy are similar to those in the Nf1
mice, these mice provide a faithful model
in which to study the induction of neo-
plasms in individuals treated for cancer.
The model closely resembles the human
experience, since related neural crest
tumors, soft tissue sarcomas, and a spe-
cial form of myeloid leukemia are seen in
both cases. Furthermore, the induction
of secondary tumors by RAD and/or an
alkylating agent, even in individuals not
known to be genetically predisposed,
also parallels the human experience. In
addition, the mechanism of solid tumor
formation is also similar to that seen in
humans, LOH of a tumor suppressor. As
in humans, the myeloid neoplasms do
not appear to use this mechanism but
may result from translocation and onco-
gene activation. NF1 patients sponta-
neously develop myeloid neoplasms
similar to those in Nf1 mice treated with
RAD alone. That fewer leukemias are
seen in RAD/CY-treated mice parallels
the finding that leukemia as an SMN was
not associated with therapeutic RAD in
children, since children are rarely treated
with RAD alone (Tucker et al., 1987b).
Nf1 mice in these experiments also
developed neural crest and myeloid
tumors without treatment, but more solid
tumors after RAD/CY and RAD alone
than controls similarly treated. An unex-
pected finding was the development of
four breast cancers in the RAD/CY-treat-
ed group of susceptible mice. Breast
cancer, the hallmark of the Li-Fraumeni
syndrome, is associated with mutations
in TP53, and with sarcomas in young
family members. While these individuals
are also known to develop multiple neo-
plasms, the role of therapy in accelerat-
ing their production is not yet clear
(Malkin et al., 1990). Gorlin syndrome, a
condition in which basal cell carcinomas
occur at an earlier than expected age, is
similar to NF1 in providing an example of
the interaction of genes and environ-
ment; RAD accelerates the development
of basal cell carcinomas in the field of
RAD for medulloblastoma, an embryonal
neoplasm that occurs in children with the
syndrome (Evans et al., 1991).
Pediatric oncologists are also familiar
with the exaggerated effects of RAD in
ataxia telangiectasia (ATM), a recessive
condition characterized by failure to repair
DNA. It has been proposed that heterozy-
gotes, who constitute as many as 1% of
the population, might be more likely than
others to develop SMNs following RAD;
evidence for this mechanism in women
who develop breast cancer following
chest irradiation is still being explored.
In addition to providing an intellectu-
ally satisfying model for the study of the
tumors that result from genetic predispo-
sition and therapy, numerous questions
regarding SMNs in children, discussed
by the authors, might be addressed
using Nf1 mice without having to wait
years for the answers. For example, are
there other drugs or combinations that
either increase the incidence of SMNs or
provide protection from the effects of
RAD or chemotherapy, and how do these
maneuvers alter the latent period
between exposure and SMNs? In the
case of RAD, could the well-known direct
dose rate effect of RAD upon mutation
P R E V I E W S
Table 1. Dominantly inherited cancer syndromes and associated neoplasms
Syndrome Primary tumor Secondary/associated neoplasms Gene
Genetic retinoblastoma retinoblastoma sarcomas, pineoblastoma, melanoma RB1
Li-Fraumeni sarcomas, breast adrenocortical, brain tumors, leukemia p53
Neurofibromatosis type 1 neurofibromas neurofibrosarcoma, AML, JMML, glioma NF1
Neurofibromatosis type 2 vestibular schwannomas meningiomas, astrocytomas, ependymomas NF2
Tuberous sclerosis renal brain tumors TSC1,2
von Hippel-Lindau renal brain tumors, pheochromocytoma VHL
Nevoid basal cell carcinoma (Gorlin syndrome) basal cell carcinoma medulloblastoma PTCH
Familial adenomatous polyposis colorectal colon, hepatoblastoma, thyroid, desmoid APC
Hereditary nonpolyposis colorectal cancer colorectal endometrial, ovarian, gastric, pancreatic MSH2/MLH1
Familial breast cancer 1 breast ovarian BRCA1
Familial breast cancer 2 breast pancreatic, ovarian BRCA2
AML, acute myelogenous leukemia; JMML, juvenile myelomonocytic leukemia.
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be employed to reduce SMNs by using
the same dose at lower dose rates?
This research encourages us to
believe that the great progress in curing
children with cancer and improving the
quality of their survival will continue so
long as pediatric oncologists, including
Dr. Shannon, ponder a child’s full life
span.
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